Research programme : RNA based cancer therapeutics - Lisata Therapeutics
Alternative Names: Research programme : nucleic acid-based therapies - Lisata TherapeuticsLatest Information Update: 02 Dec 2022
At a glance
- Originator Lisata Therapeutics
- Class Antineoplastics; RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Dec 2022 Preclinical trials in Solid tumours in USA (Parenteral) (Lisata Therapeutics pipeline, December 2022)
- 02 Dec 2022 Lisata Therapeutics plans a phase I trial for solid tumours in 2024(Lisata Therapeutics pipeline, December 2022)
- 15 Sep 2022 Early research in Solid tumours in USA (Parenteral) before September 2022